Lymphocyte Subpopulations and Interleukin Levels in High-Risk Melanoma Patients Treated With High-Dose Interferon A-2B-Reference-Cited by-同舟云学术

Lymphocyte Subpopulations and Interleukin Levels in High-Risk Melanoma Patients Treated With High-Dose Interferon A-2B

Published:2002-12 Issue:6 Volume:25 Page:591-596
ISSN:0277-3732
Container-title:American Journal of Clinical Oncology
language:en
Short-container-title:American Journal of Clinical Oncology

Author:

Gogas Helen,Paterakis George,Frangia Konstantina,Bafaloukos Dimitrios,Pectasides Dimitrios,Kalofonos Haralambos P.,Loukopoulos Dimitrios,Stavropoulou-Giokas Cathrin,Ioannovich John,Mihm Martin C.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference17 articles.

1. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

2. Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastases

3. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group.

4. Presidential Symposium

5. Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Baseline laboratory parameters predicting clinical outcome in melanoma patients treated with ipilimumab: a single-centre analysis;Journal of the European Academy of Dermatology and Venereology;2017-11-22

2. Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study);Cancer Immunology, Immunotherapy;2013-04-27

3. Neoadjuvant Treatment of Regional Stage IIIB Melanoma With High-Dose Interferon Alfa-2b Induces Objective Tumor Regression in Association With Modulation of Tumor Infiltrating Host Cellular Immune Responses;Journal of Clinical Oncology;2006-07-01

4. Clinical and Immunologic Effects of Subcutaneously Administered Interleukin-12 and Interferon Alfa-2b: Phase I Trial of Patients With Metastatic Renal Cell Carcinoma or Malignant Melanoma;Journal of Clinical Oncology;2004-07-15